Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Inflammatory Breast Cancer (IBC)
and you are
over 18
years old
This is a second phase trial assessing
efficacy and side effects of the new treatment.
Show me locations

The purpose

This research study is studying Ruxolitinib as possible treatment for Inflammatory Breast Cancer (IBC). The Following drugs will be use in combination with Ruxolinitinib. - Paclitaxel (also called Taxol) - Doxorubicin also called Adriamycin - Cyclophosphamide, also called Cytoxan

Provided treatments

  • Drug: Ruxolitinib
  • Drug: Paclitaxel
  • Drug: Doxorubicin
  • Drug: Cyclophosphamide
Wondering what is the locations section for?
We will connect you to the doctor responsible for this trial and help you get more information.

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT02876302. The sponsor of the trial is Dana-Farber Cancer Institute and it is looking for 64 volunteers for the current phase.
Official trial title:
Phase II Study Of Combination Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer